Agenus Inc. is a clinical-stage biotechnology company focused on developing immunotherapies targeting cancer and infectious diseases. The company operates through multiple therapeutic platforms, including Retrocyte Display, an antibody expression technology for identifying fully human and humanized monoclonal antibodies, and display technologies that enable antibody discovery. Its primary approach centers on checkpoint inhibitors and immune-activating agents designed to enhance the body's anti-tumor response.
The company's pipeline includes several candidates in clinical development across oncology indications. Balstilimab, a PD-1 blocking antibody, represents a core asset, alongside AGEN1181, a CTLA-4 blocking antibody in Phase 2 trials for metastatic colorectal cancer, pancreatic cancer, and melanoma. Additional programs include AGEN2373 (CD137 monospecific), AGEN1423 (CD73/TGFß TRAP), and MK-4830 (ILT4 targeting), among others. The company also develops QS-21 Stimulon, a saponin-based vaccine adjuvant. Agenus operates under established trademarks including Agenus, MiNK, Prophage, and Retrocyte Display.
Agenus maintains collaborations with major pharmaceutical companies including Bristol-Myers Squibb, Incyte Corporation, Merck, Gilead Sciences, and UroGen Pharma. The company is headquartered in Lexington, Massachusetts, and operates with approximately 316 full-time employees. Founded in 1994 as Antigenics Inc., it rebranded as Agenus in 2011 and is incorporated in Delaware.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | $-10.59 | $-10.59 | -1434.8% | |
| 2023 | $-0.69 | $-0.69 | +11.5% | |
| 2022 | $-0.78 | $-0.78 | — | |
| 2021 | — | — | — | |
| 2020 | $-0.22 | $-0.22 | +0.0% | |
| 2019 | $-0.22 | $-0.22 | — | |
| 2018 | — | — | — | |
| 2017 | — | — | — | |
| 2016 | — | — | — | |
| 2015 | — | — | — | |
| 2014 | — | — | — | |
| 2013 | — | $-0.16 | +30.4% | |
| 2012 | $-0.23 | $-0.23 | — | |
| 2011 | — | — | — |
| Report Date | Filed | Accession Number | |
|---|---|---|---|
| 2024-12-31 | 2025-03-17 | 0000950170-25-040289 | SEC ↗ |
| 2023-12-31 | 2024-03-14 | 0000950170-24-031620 | SEC ↗ |
| 2022-12-31 | 2023-03-16 | 0000950170-23-008517 | SEC ↗ |
| 2021-12-31 | 2022-03-01 | 0001564590-22-007867 | SEC ↗ |
| 2020-12-31 | 2021-03-16 | 0001564590-21-013619 | SEC ↗ |
| 2019-12-31 | 2020-03-16 | 0001564590-20-011221 | SEC ↗ |
| 2018-12-31 | 2019-03-18 | 0001564590-19-008311 | SEC ↗ |
| 2017-12-31 | 2018-03-16 | 0001564590-18-006093 | SEC ↗ |
| 2016-12-31 | 2017-03-16 | 0001564590-17-004618 | SEC ↗ |
| 2015-12-31 | 2016-03-15 | 0001564590-16-014840 | SEC ↗ |
| 2014-12-31 | 2015-03-16 | 0001628280-15-001809 | SEC ↗ |
| 2013-12-31 | 2014-03-07 | 0001445305-14-000937 | SEC ↗ |